Challenging the Odds: Long-Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co-Mutations Treated With Upfront Radiotherapy and Targeted Therapy

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Article numbere31929
JournalPediatric Blood and Cancer
Volume72
Issue number10
DOIs
StatePublished - Oct 2025

Keywords

  • BRAF-targeted therapy
  • H3 K27-altered
  • dabrafenib
  • diffuse midline glioma
  • trametinib

Cite this